Slingshot members are tracking this event:
Phase 1b study assessing AFM13/KEYTRUDA combo in lymphoma to be initiated in the first half of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Aug 10, 2016
Don’t see a project related to the catalyst you care about?
Related Keywords Lymphoma, Afm13, Keytruda, Combo, Phase 1b Initiation, Clinical Research Collaboration